Primary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study

BMJ Open

Volumn 3, Issue 12, 2013, Pages

  Morgan, Christopher Ll ^a   Owens, David R ^b   Aubonnet, Patrick ^c   Carr, Emma S M ^c   Jenkins Jones, Sara ^d   Poole, Chris D ^a   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

^d Pharmatelligence ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84890812726     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004025     Document Type: Article

References (39)

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
2. Sivaprasad S, Gupta B, Gulliford MC, et al. Ethnic variation in the prevalence of visual impairment in people attending diabetic retinopathy screening in the United Kingdom (DRIVE UK). PLoS ONE 2012;7:e39608.
3. Kohner E, Allwinkle J, Andrews J, et al. Saint Vincent and improving diabetes care: report of the Visual Handicap Group. Diabet Med 1996;13(Suppl 4):S13-26.
4. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006;6:58.
5. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy. J Med Screen 2008;15:1-4.
6. Leese GP, Morris AD, Olson J. A national retinal screening programme for diabetes in Scotland. Diabet Med 2003;20:962-4.
7. Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012;344:e874.
8. Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert Opin Biol Ther 2011;12:93-105.
9. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
10. ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
11. Medicines and Healthcare products Regulatory Agency. The Clinical Practice Research Datalink. 2012. http://www.cprd.com
12. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
14. International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium: International Diabetes Federation, 2011. http://www.idf.org/ diabetesatlas
15. Klein BE, Moss SE, Klein R, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991;98:1261-5.
16. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
17. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008;115:1869-75.
18. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-18.
19. Rema M, Srivastava BK, Anitha B, et al. Association of serum lipids with diabetic retinopathy in urban south Indians - the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med 2006;23:1029-36.
20. Gupta A, Gupta V, Thapar S, et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-82.
21. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
22. Wong TY, Simó R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154:6-12.
23. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
24. Tserentsoodol N, Gordiyenko NV, Pascual I, et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 2006;12:1319-33.
25. Simó R, García-Ramírez M, Higuera M, et al. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol 2009;147:319-25.
26. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-41.
27. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-54.
28. Marx N, Sukhova GK, Collins T, et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99:3125-31.
29. Hiukka A, Maranghi M, Matikainen N, et al. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-63.
30. Villarroel M, Garcia-Ramírez M, Corraliza L, et al. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1ß by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011;54:1543-53.
31. Miranda S, González-Rodríguez Á, García-Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 2012;227:2352-62.
32. Trudeau K, Roy S, Guo W, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci 2011;52:6348-54.
33. Meissner M, Stein M, Urbich C, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004;94:324-32.
34. Sapieha P, Hamel D, Shao Z, et al. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010;42:5-12.
35. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009;105:114-27.
36. Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84:886-93.
37. Okayasu T, Tomizawa A, Suzuki K, et al. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008;82:884-91.
38. Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34:1341-6.
39. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-90.